Glucocerebrosidase deficiency and mitochondrial impairment in experimental Parkinson disease

Keyphrases

• Mitochondrial Impairment 100%
• Glucocerebrosidase Deficiency 100%
• Miglustat 100%
• Experimental Parkinson's Disease 100%
• 1-methyl-4-phenylpyridinium 75%
• Glucocerebrosidase Activity 75%
• Conduritol B Epoxide 75%
• Parkinson's Disease 50%
• Alpha-synuclein (α-syn) 50%
• Glucosylceramide Synthase 50%
• 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 50%
• Glucocerebroside 50%
• Induced Toxicity 50%
• Autosomal Recessive 25%
• Disease Genes 25%
• Gaucher Disease 25%
• Glucocerebrosidase 25%
• Glucocerebrosidase Gene 25%
• Dopaminergic Neurons 25%
• Intoxication 25%
• Functional Deficiency 25%
• Vulnerability Factors 25%
• Cellular Respiration 25%
• Lysosomal Enzymes 25%
• Complex I Activity 25%
• Subchronic 25%
• Genetic Vulnerability 25%
• Toxicity in Vitro 25%
• Glucocerebrosidase mutations 25%

Neuroscience

• Parkinson's Disease 100%
• Glucosylceramidase 100%
• Miglustat 57%
• Epoxide 42%
• MPP+ 42%
• In Vitro 28%
• Ceramide Glucosyltransferase 28%
• Glucosylceramide 28%
• Tetrahydropyridine 28%
• In Vivo 14%
• Dopaminergic Neuron 14%
• Cellular Respiration 14%
• Alpha-Synuclein 14%
• Gene Mutation 14%
• Autosomal Recessive Disorder 14%
• Lysosome Enzyme 14%
• Toxic Injury 14%